Eli Lilly & Co. Community Page | What other sites are saying about Eli Lilly & Co.

Eli Lilly & Co.

(NY: LLY)

55.02 USD UNCHANGED

Official Closing Price / Updated: 6:40 PM EDT, May 20, 2013 / Add to My Watchlist

(LLY) Community Analysis from

READ MORE (LLY)

Bulls REASONS TO BUY

90% agree 43 votes	Zyprexa incredibly profitable
50% agree 2 votes	Strong dollar spurs quarterly profit

View all Bulls Reasons

Bears REASONS TO SELL

26% agree 15 votes	Zyprexa will lose patent protection in 2011
37% agree 37 votes	Zyprexa causes Diabetes

View all Bears Reasons

May 21, 2013

(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate

(Stock Blog Hub, 5/3/13)

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary...(read more)

(OGXI) OncoGenex Pharmaceuticals’ OGX-427 Progresses

(Stock Blog Hub, 4/21/13)

OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment...(read more)

A Mixed Bag Of News For Eli Lilly’s Alimta Drug

(ValueWalk.com, 8/24/12)

According to a report in BusinessWeek , pharmaceutical major, Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), has won its case in the U.S. Court of Appeals relating to patent protection for its...(read more)

View all posts about Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY) Company Overview

There is no analysis for LLY yet. But you can go to Wikinvest to help create one!

What's in this LLY analysis on Wikinvest...